View in EDS

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.

Saved in:
Bibliographic Details
Title: Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
Authors: Hart LL; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL, USA; Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: llhart@wakehealth.edu., Im SA; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea., Tolaney SM; Dana-Farber Cancer Institute, Boston, MA, USA., Campone M; Institut de Cancérologie de l'Ouest/René Gauducheau Centre de Recherche en Cancérologie, St. Herblain, France., Pluard T; Saint Luke's Cancer Institute, Kansas City, MO, USA., Sousa B; Breast Unit, Champalimaud Clinical and Research Center/Champalimaud Foundation, Lisbon, Portugal., Freyer G; Oncology Department, Hôpital Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL) and Université de Lyon, France., Decker T; Gemeinschaftspraxis für Hämatologie und Onkologie Ravensburg, Germany., Kalinsky K; Winship Cancer Institute at Emory University, Atlanta, GA, USA., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Gao M; Novartis Pharma AG, Basel, Switzerland., Hu H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Kuemmel S; Department of Gynecology with Breast Unit, Charité Hospital Berlin, Germany; Interdisciplinary Breast Unit, Kliniken Essen Mitte, Essen, Germany.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Feb 25; Vol. 217, pp. 115225. Date of Electronic Publication: 2025 Jan 08.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39826197
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hart+LL%22">Hart LL</searchLink>; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL, USA; Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: llhart@wakehealth.edu.<br /><searchLink fieldCode="AU" term="%22Im+SA%22">Im SA</searchLink>; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Campone+M%22">Campone M</searchLink>; Institut de Cancérologie de l'Ouest/René Gauducheau Centre de Recherche en Cancérologie, St. Herblain, France.<br /><searchLink fieldCode="AU" term="%22Pluard+T%22">Pluard T</searchLink>; Saint Luke's Cancer Institute, Kansas City, MO, USA.<br /><searchLink fieldCode="AU" term="%22Sousa+B%22">Sousa B</searchLink>; Breast Unit, Champalimaud Clinical and Research Center/Champalimaud Foundation, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Freyer+G%22">Freyer G</searchLink>; Oncology Department, Hôpital Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL) and Université de Lyon, France.<br /><searchLink fieldCode="AU" term="%22Decker+T%22">Decker T</searchLink>; Gemeinschaftspraxis für Hämatologie und Onkologie Ravensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Kalinsky+K%22">Kalinsky K</searchLink>; Winship Cancer Institute at Emory University, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Sopher+G%22">Sopher G</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Gao+M%22">Gao M</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hu+H%22">Hu H</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Kuemmel+S%22">Kuemmel S</searchLink>; Department of Gynecology with Breast Unit, Charité Hospital Berlin, Germany; Interdisciplinary Breast Unit, Kliniken Essen Mitte, Essen, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229005373%22">European journal of cancer (Oxford, England : 1990)</searchLink> [Eur J Cancer] 2025 Feb 25; Vol. 217, pp. 115225. <i>Date of Electronic Publication: </i>2025 Jan 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9005373 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0852 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209598049%22">09598049 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39826197
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ejca.2025.115225
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 115225
    Titles:
      – TitleFull: Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hart LL
      – PersonEntity:
          Name:
            NameFull: Im SA
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
      – PersonEntity:
          Name:
            NameFull: Campone M
      – PersonEntity:
          Name:
            NameFull: Pluard T
      – PersonEntity:
          Name:
            NameFull: Sousa B
      – PersonEntity:
          Name:
            NameFull: Freyer G
      – PersonEntity:
          Name:
            NameFull: Decker T
      – PersonEntity:
          Name:
            NameFull: Kalinsky K
      – PersonEntity:
          Name:
            NameFull: Sopher G
      – PersonEntity:
          Name:
            NameFull: Gao M
      – PersonEntity:
          Name:
            NameFull: Hu H
      – PersonEntity:
          Name:
            NameFull: Kuemmel S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 02
              Text: 2025 Feb 25
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1879-0852
          Numbering:
            – Type: volume
              Value: 217
          Titles:
            – TitleFull: European journal of cancer (Oxford, England : 1990)
              Type: main
ResultId 1